Moderna said Wednesday its finished its application to drug regulators for approval for its COVID-19 vaccine. “This BLA submission for our COVID-19 vaccine, which we began in June, is an important milestone in our battle against COVID-19 and for Moderna, as this is the first BLA submission in our company’s history,” Stéphane Bancel, Moderna’s CEO, said in a statement, referring to the Biologics License Application. Moderna began submitting sections of the application in June and periodically sent more data to the Food and Drug Administration (FDA), including clinical data from a Phase 3 clinical trial that enrolled more than 30,000 participants and was conducted in collaboration with the National Institute of Allergy and Infectious Disease (NIAID) and two other agencies. According to the Massachusetts-based biotechnology firm, the trial showed that the vaccine was 93 percent effective in preventing infection from the CCP (Chinese Communist Party) virus, which causes COVID-19. The …